SEC Tracker
Get the app

Regeneron Pharmaceuticals REGN

Huda Y Zoghbi (Director) plans to sell 800 REGN shares, about $640,000

Form
144
Filed
Importance
Routine
  1. Approximate sale date: Aug 10, 2026
  2. Broker: UBS Financial Services, Inc.
  3. Shares acquired by: Exercise of stock options
  4. 10b5-1 plan adopted: Nov 20, 2025

All of Huda Y Zoghbi's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 800 shares at $800 on Aug 10, 2026 · Form 4

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Regeneron Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Zoetis ZTS public float $69.2B, Jun 30, 2025
  2. Idexx Laboratories IDXX public float $42.9B, Jun 30, 2025
  3. Alnylam Pharmaceuticals ALNY public float $42.6B, Jun 30, 2025
  4. Bristol Myers Squibb BMY public float $94.2B, Jun 30, 2025
  5. Gilead Sciences GILD public float $103.2B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.